An EWAS in a cohort consisting of pre‐symptomatic and symptomatic HD mutation carriers, and healthy controls, has shown promising results by identifying significant DNA methylation changes in CLDN16, DDC and NXT2 in the pre‐symptomatic HD individuals compared with controls, but not upon the comparison of symptomatic patients with controls [132]. This evidence concerns the gene CLDN16 and Huntington disease.